The myelodysplastic syndromes flow cytometric score: a 3-parameter prognostic flow cytometric scoring system
|
Oct 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Raising the bar for lower-risk myelodysplastic syndromes
|
Apr 2023
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
Raising the bar for lower-risk myelodysplastic syndromes
|
Jun 2023
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria
|
Dec 2019
|
Leukemia & Lymphoma
|
aplastic anemia
|
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey
|
Jun 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|